These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 26376647)

  • 1. Clinical Utility of a Plasma Protein Classifier for Indeterminate Lung Nodules.
    Vachani A; Hammoud Z; Springmeyer S; Cohen N; Nguyen D; Williamson C; Starnes S; Hunsucker S; Law S; Li XJ; Porter A; Kearney P
    Lung; 2015 Dec; 193(6):1023-7. PubMed ID: 26376647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenesis Biomarkers May Be Useful in the Management of Patients With Indeterminate Pulmonary Nodules.
    Seder CW; Kubasiak JC; Pithadia R; Basu S; Fhied C; Tarhoni I; Davila E; Alnajjar H; Chmielewski GW; Warren WH; Liptay MJ; Borgia JA
    Ann Thorac Surg; 2015 Aug; 100(2):429-36. PubMed ID: 26138771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer.
    Massion PP; Healey GF; Peek LJ; Fredericks L; Sewell HF; Murray A; Robertson JF
    J Thorac Oncol; 2017 Mar; 12(3):578-584. PubMed ID: 27615397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinguishing patients with stage I lung cancer versus control individuals using serum mass profiling.
    Hanas JS; Peyton MD; Lerner MR; Lightfoot SA; Deb SJ; Hanas RJ; Vu NT; Kupiec TC; Stowell DE; Brackett DJ; Dubinett SM; Hocker JR
    Cancer Invest; 2014 May; 32(4):136-43. PubMed ID: 24579933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules.
    Daly S; Rinewalt D; Fhied C; Basu S; Mahon B; Liptay MJ; Hong E; Chmielewski G; Yoder MA; Shah PN; Edell ES; Maldonado F; Bungum AO; Borgia JA
    J Thorac Oncol; 2013 Jan; 8(1):31-6. PubMed ID: 23201823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer.
    Ajona D; Remirez A; Sainz C; Bertolo C; Gonzalez A; Varo N; Lozano MD; Zulueta JJ; Mesa-Guzman M; C Martin A; Perez-Palacios R; Perez-Gracia JL; Massion PP; Montuenga LM; Pio R
    Transl Res; 2021 Jul; 233():77-91. PubMed ID: 33618009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Gene Expression Classifier from Whole Blood Distinguishes Benign from Malignant Lung Nodules Detected by Low-Dose CT.
    Kossenkov AV; Qureshi R; Dawany NB; Wickramasinghe J; Liu Q; Majumdar RS; Chang C; Widura S; Kumar T; Horng WH; Konnisto E; Criner G; Tsay JJ; Pass H; Yendamuri S; Vachani A; Bauer T; Nam B; Rom WN; Showe MK; Showe LC
    Cancer Res; 2019 Jan; 79(1):263-273. PubMed ID: 30487137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A classifier integrating plasma biomarkers and radiological characteristics for distinguishing malignant from benign pulmonary nodules.
    Lin Y; Leng Q; Jiang Z; Guarnera MA; Zhou Y; Chen X; Wang H; Zhou W; Cai L; Fang H; Li J; Jin H; Wang L; Yi S; Lu W; Evers D; Fowle CB; Su Y; Jiang F
    Int J Cancer; 2017 Sep; 141(6):1240-1248. PubMed ID: 28580707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules: A non-invasive biomarker for predicting malignancy and tumour invasiveness.
    Zhou Q; Geng Q; Wang L; Huang J; Liao M; Li Y; Ding Z; Yang S; Zhao H; Shen Q; Pan C; Lou J; Lu S; Chen C; Luo Q
    EBioMedicine; 2019 Mar; 41():236-243. PubMed ID: 30872130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules.
    Li XJ; Hayward C; Fong PY; Dominguez M; Hunsucker SW; Lee LW; McLean M; Law S; Butler H; Schirm M; Gingras O; Lamontagne J; Allard R; Chelsky D; Price ND; Lam S; Massion PP; Pass H; Rom WN; Vachani A; Fang KC; Hood L; Kearney P
    Sci Transl Med; 2013 Oct; 5(207):207ra142. PubMed ID: 24132637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coexisting pulmonary nodules in operable lung cancer: prevalence and probability of malignancy.
    Ruppert AM; Lerolle U; Carette MF; Lavole A; Khalil A; Bazelly B; Antoine M; Cadranel J; Milleron B
    Lung Cancer; 2011 Nov; 74(2):233-8. PubMed ID: 21511355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial.
    Silvestri GA; Tanner NT; Kearney P; Vachani A; Massion PP; Porter A; Springmeyer SC; Fang KC; Midthun D; Mazzone PJ;
    Chest; 2018 Sep; 154(3):491-500. PubMed ID: 29496499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of a multiprotein plasma classifier to identify benign lung nodules.
    Vachani A; Pass HI; Rom WN; Midthun DE; Edell ES; Laviolette M; Li XJ; Fong PY; Hunsucker SW; Hayward C; Mazzone PJ; Madtes DK; Miller YE; Walker MG; Shi J; Kearney P; Fang KC; Massion PP
    J Thorac Oncol; 2015 Apr; 10(4):629-37. PubMed ID: 25590604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics and work-up of small to intermediate-sized pulmonary nodules in a Chinese dedicated cancer hospital.
    Cui X; Han D; Heuvelmans MA; Du Y; Zhao Y; Zhang L; Groen HJM; de Bock GH; Dorrius MD; Oudkerk M; Vliegenthart R; Ye Z
    Cancer Biol Med; 2020 Feb; 17(1):199-207. PubMed ID: 32296586
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation and management of solitary and multiple pulmonary nodules.
    Viggiano RW; Swensen SJ; Rosenow EC
    Clin Chest Med; 1992 Mar; 13(1):83-95. PubMed ID: 1582151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Value of Combined Detection of Cytokines and Tumor Markers in the 
Differential Diagnosis of Benign and Malignant Solitary Pulmonary Nodules].
    Shi J; Liu X; Ming Z; Li W; Lv X; Yang X; Wang Y; Zhang M; Yang S
    Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):426-433. PubMed ID: 34157802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining serum miRNAs, CEA, and CYFRA21-1 with imaging and clinical features to distinguish benign and malignant pulmonary nodules: a pilot study : Xianfeng Li et al.: Combining biomarker, imaging, and clinical features to distinguish pulmonary nodules.
    Li X; Zhang Q; Jin X; Cao L
    World J Surg Oncol; 2017 May; 15(1):107. PubMed ID: 28545454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computed tomography-guided percutaneous needle biopsy of pulmonary nodules: impact of nodule size on diagnostic accuracy.
    Kothary N; Lock L; Sze DY; Hofmann LV
    Clin Lung Cancer; 2009 Sep; 10(5):360-3. PubMed ID: 19808195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of preoperative prediction factors of tumor subtypes for patients with solitary ground-glass opacity pulmonary nodules.
    Li M; Wang Y; Chen Y; Zhang Z
    J Cardiothorac Surg; 2018 Jan; 13(1):9. PubMed ID: 29343293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the Patient With a Pulmonary Nodule: A Review.
    Mazzone PJ; Lam L
    JAMA; 2022 Jan; 327(3):264-273. PubMed ID: 35040882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.